Key Documents

View All Documentation

G8173

GW833972A

Name: GW833972A
Brand: SIGMA

≥98% (HPLC), powder

Synonym(s):

2-[(3-chlorophenyl)amino]-N-(4-pyridinylmethyl)-4-(trifluoromethyl)-5-Pyrimidinecarboxamide hydrochloride

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₁₈H₁₃ClF₃N₅O · HCl

CAS Number:

1092502-33-4

Molecular Weight:

444.24

NACRES:

NA.77

PubChem Substance ID:

329799976

UNSPSC Code:

12352200

MDL number:

MFCD18452844

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Storage condition:

desiccated

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

powder

drug control

regulated under CDSA - not available from Sigma-Aldrich Canada

storage condition

desiccated

color

off-white to light brown

solubility

DMSO: ≥20 mg/mL

storage temp.

2-8°C

SMILES string

Cl.FC(F)(F)c1nc(Nc2cccc(Cl)c2)ncc1C(=O)NCc3ccncc3

InChI

1S/C18H13ClF3N5O.ClH/c19-12-2-1-3-13(8-12)26-17-25-10-14(15(27-17)18(20,21)22)16(28)24-9-11-4-6-23-7-5-11;/h1-8,10H,9H2,(H,24,28)(H,25,26,27);1H

InChI key

UBHSVFAUAKIVKL-UHFFFAOYSA-N

Application

GW833972A, a selective CB2 cannabinoid receptor agonist, may be used separately or in comparison to other cannabinoid receptor agonist and antagonists to differentiate and characterize the CB2 cannabinoid receptor. GW833972A may be used to help verify that an observed physiological response is cannabinoid receptor CB2-dependent.

Biochem/physiol Actions

GW833972A is a CB2 cannabinoid receptor agonist with 1000-fold selectivity relative to CB1.

GW833972A is a CB2 cannabinoid receptor agonist with 1000-fold selectivity relative to CB1. It is, however, 15-fold less potent than HU210 for CB2 (Ki 7.8 vs. 0.52 nM). The antitumor compound oxaliplatin induces marked hypersensitivity to cold, heat, and chemical pain stimuli (to the point where oxaliplatin therapy has to be discontinued). The hyperalgesia effect is almost completely blocked by pretreatment with GW833972A.

GW833972A is a CB2 receptor agonist with 1000-fold selectivity relative to CB1.

The compound was used to determine the role of CB2 in airway sensory nerve function.

pictograms

GHS06

signalword

Danger

hcodes

H301,H315,H319,H335,H413

pcodes

P273 - P301 + P310 + P330 - P302 + P352 - P305 + P351 + P338

Hazard Classifications

Acute Tox. 3 Oral - Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

100M4622V

110M4622

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

The clinical features and long-term sequelae of invasive meningococcal disease in children.

Chen Stein-Zamir et al.

The Pediatric infectious disease journal, 33(7), 777-779 (2014-03-14)

We evaluated the outcome of invasive meningococcal disease in children <15 years of age (n = 181). Neisseria meningitidis serogroup B comprised 78% of bacterial isolates. Case fatality rate was 11.6%. In follow-up interviews (115/160 survivors, 72%), at least 1

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.

Agnès Hartemann et al.

The lancet. Diabetes & endocrinology, 1(4), 295-305 (2014-03-14)

An improper balance of regulatory/effector T (Treg/Teff) cells is central to the development of autoimmune diseases, including type 1 diabetes. We previously showed that low-dose interleukin 2 (IL2) induced Treg cell expansion and activation and clinical improvement in patients with

Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.

Michael Mannstadt et al.

The lancet. Diabetes & endocrinology, 1(4), 275-283 (2014-03-14)

Hypoparathyroidism results in impaired mineral homoeostasis, including hypocalcaemia and hyperphosphataemia. Treatment with high-dose oral calcium and active vitamin D does not provide adequate or consistent control of biochemical indices and can lead to serious long-term complications. We aimed to test

Vascular risk factors, large-artery atheroma, and brain white matter hyperintensities.

Joanna M Wardlaw et al.

Neurology, 82(15), 1331-1338 (2014-03-14)

To determine the magnitude of potentially causal relationships among vascular risk factors (VRFs), large-artery atheromatous disease (LAD), and cerebral white matter hyperintensities (WMH) in 2 prospective cohorts. We assessed VRFs (history and measured variables), LAD (in carotid, coronary, and leg

Increased risk of chronic obstructive pulmonary disease in patients with systemic lupus erythematosus: a population-based cohort study.

Te-Chun Shen et al.

PloS one, 9(3), e91821-e91821 (2014-03-14)

There is increasing evidence that autoimmune disease is associated with development of chronic obstructive pulmonary disease (COPD). We aim to assess the relationship between systemic lupus erythematosus (SLE) and COPD risk in a nationwide population. We conducted a retrospective cohort

View All Related Papers

Global Trade Item Number

SKU	GTIN
G8173-25MG	04061833234556
G8173-5MG	04061833643846

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service